Theodore T. Wang Buys 50,000 Shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) Stock
Bellerophon Therapeutics Inc (NASDAQ:BLPH) Director Theodore T. Wang bought 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was purchased at an average price of $0.64 per share, for a total transaction of $32,000.00. Following the acquisition, the director now directly owns 584,479 shares in the company, valued at $374,066.56. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
NASDAQ:BLPH opened at $0.62 on Monday. The stock has a market capitalization of $42.73 million, a price-to-earnings ratio of -1.82 and a beta of -0.02. Bellerophon Therapeutics Inc has a 12 month low of $0.47 and a 12 month high of $3.30. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.18.
Bellerophon Therapeutics (NASDAQ:BLPH) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.01 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.11. Research analysts predict that Bellerophon Therapeutics Inc will post -0.21 earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc lifted its holdings in shares of Bellerophon Therapeutics by 2.5% in the 3rd quarter. Vanguard Group Inc now owns 1,023,533 shares of the biotechnology company’s stock valued at $1,105,000 after purchasing an additional 25,300 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Bellerophon Therapeutics by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 232,890 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 27,027 shares during the last quarter. Finally, Arch Venture Corp purchased a new stake in shares of Bellerophon Therapeutics in the 1st quarter valued at about $631,000. Hedge funds and other institutional investors own 54.68% of the company’s stock.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.
Read More: Economic Reports
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.